Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue

Autor: Wojciech Jankowski, Joseph McGill, H.A.Daniel Lagassé, Stepan Surov, Gary Bembridge, Campbell Bunce, Edward Cloake, Mark H. Fogg, Katarzyna I. Jankowska, Abdul Khan, Joseph Marcotrigiano, Mikhail V. Ovanesov, Zuben E. Sauna

Publikováno v: Blood Advances, Vol 3, Iss 17, Pp 2668-2678 (2019)

Abstract: Vatreptacog alfa (VA), a recombinant activated human factor VII (rFVIIa) variant with 3 amino acid substitutions, was developed to provide increased procoagulant activity in hemophilia patients with inhibitors to factor VIII or factor IX. I

Externí odkaz: https://doaj.org/article/ef7a790689d44f5b9a7802adb877facf

An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection.

Autor: Makoto Ohashi, Mark H Fogg, Nina Orlova, Carol Quink, Fred Wang

Publikováno v: PLoS Pathogens, Vol 8, Iss 12, p e1003095 (2012)

Acute Epstein-Barr virus (EBV) infection is the most common cause of Infectious Mononucleosis. Nearly all adult humans harbor life-long, persistent EBV infection which can lead to development of cancers including Hodgkin Lymphoma, Burkitt Lymphoma, n

Externí odkaz: https://doaj.org/article/71829be43ccf47019cc093fc18d640ff

Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue

Autor: Gary Bembridge, Stepan S Surov, H.A. Daniel Lagassé, Mikhail V Ovanesov, Zuben E. Sauna, Wojciech Jankowski, Mark H. Fogg, Edward A. Cloake, Joseph Marcotrigiano, Joseph R. McGill, Campbell Bunce, Katarzyna I. Jankowska, Abdul Ghafoor Khan

Publikováno v: Blood advances. 3(17)

Vatreptacog alfa (VA), a recombinant activated human factor VII (rFVIIa) variant with 3 amino acid substitutions, was developed to provide increased procoagulant activity in hemophilia patients with inhibitors to factor VIII or factor IX. In phase 3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b9b7850c78bb7178ede66f1fb342efe
https://pubmed.ncbi.nlm.nih.gov/31506285

Therapeutic Vaccination against the Rhesus Lymphocryptovirus EBNA-1 Homologue, rhEBNA-1, Elicits T Cell Responses to Novel Epitopes in Rhesus Macaques

Autor: David H. O’Connor, Mark H. Fogg, Roger W. Wiseman, Paul M. Lieberman, Fred Wang, R.M. Leskowitz, Eduardo Lani Volpe da Silveira, Francois Villinger, Hildegund C.J. Ertl

Publikováno v: Journal of Virology. 87:13904-13910

Epstein-Barr virus (EBV) is a vaccine/immunotherapy target due to its association with several human malignancies. EBNA-1 is an EBV protein consistently expressed in all EBV-associated cancers. Herein, EBNA-1-specific T cell epitopes were evaluated a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebe7f65cc1ff0e978a766610e2cf6105
https://doi.org/10.1128/jvi.01947-13

A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead

Autor: Tim Jones, Matthew P. Baker, Francis J. Carr, Mark H. Fogg, Robert George Edward Holgate, Arron Hearn, Javier Lacadena, Kurt R. Gehlsen, Dorota Kozub

Publikováno v: E-Prints Complutense: Archivo Institucional de la UCM
Universidad Complutense de Madrid
Protein Engineering, Design and Selection
E-Prints Complutense. Archivo Institucional de la UCM
instname

Fungal ribotoxins that block protein synthesis can be useful warheads in the context of a targeted immunotoxin. α-Sarcin is a small (17 kDa) fungal ribonuclease produced by Aspergillus giganteus that functions by catalytically cleaving a single phos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::209fe0a1eed852bfde9eaf83aad40f8f